dChan
Anonymous ID: 6b3c45 Sept. 30, 2023, 10:13 a.m. No.19639109   🗄️.is 🔗kun   >>9172 >>9272

Kash this a.m. on X22-

@23:39

I think Biden has made it abundantly clear he's not going anywhere, and the only scenario where he would go somewhere, and this is how evil the democrats are and how twisted their version of justice is, I think they'll charge Hunter Biden with more crimes. Severe crimes. Um, and I think they'll tie in some of the Biden family, which will force Joe Biden to pardon his kid. Now that has to happen I would say in the next three, four months here, maybe five. Um, once he does that then he's politically nuked. Then he will be shown the door and the Democrats will have the ability to airdrop in their candidate.

 

Sooo, about 5 months reference again, like Trump said.

Anonymous ID: 6b3c45 Sept. 30, 2023, 10:34 a.m. No.19639224   🗄️.is 🔗kun   >>9233 >>9319 >>9404

>>19639149

how about we arrest the homeless addicts for vagrancy and offer them an actual treatment:

Monoclonal Antibodies

 

https://www.kuow.org/stories/it-s-almost-like-a-light-switch-everett-doctor-touts-potential-of-new-drug-to-break-meth-addiction

 

What is really amazing with this particular treatment is that folks come in affected by meth, they get the treatment, and it's almost like a light switch. Within 30 minutes to an hour they're no longer affected by the drug. They're making plans for getting clean or trying to get back into housing. That's the real promise, I think, that this agent has is that there are a lot of people out there who are using who don't want to use, but it's so hard to break the cycle. This drug may be that way to break the cycle.

 

https://www.fredhutch.org/en/news/spotlight/2023/01/hb-lacourse-cellreports.html

 

Focusing on common drugs—nicotine, heroin, morphine, oxycodone, fentanyl, and fentanyl analogs—Dr. Pravetoni’s group generated drug-specific antibodies which they showed to reduce drug concentrations in the brain and improve behavioral effects of drug use in several animal models. While they had evidence that these antibodies worked, the crucial piece of the puzzle they were missing—the piece which Dr. Pancera was able to provide—was exactly how they worked. Purifying these drug-specific antibodies, Rodarte and colleagues solved X-ray crystal structures of drug-antibody conjugates, which they analyzed to determine the mechanism of binding at atomic resolution.

 

To say that Rodarte and Pancera were surprised at what they found would be an understatement. “Since these are small molecules, they don’t have too many chemical groups which antibodies can bind in the first place,” Rodarte says. “But we were still pretty shocked at how similarly these diverse drugs were bound.” Thus, while each antibody was exquisitely specific to each drug, the chemical groups which were common among the drugs were bound in similar poses and by similar amino acids on the respective antibody. In stark contrast, when the team compared their structures to published structures of the drugs bound to their endogenous receptors in the brain, they found that the binding modes were completely different. “In hindsight, it makes sense—the drug-receptor pairs evolved promiscuity and rapid on-off binding according to their function,” Rodarte explains. “The kind of ‘high-affinity, low dissociation’ binding we look for in antibodies is distinct from that.”